European Journal of Nuclear Medicine and Molecular Imaging最新文献

{"title":"Convection-enhanced delivery of [²²⁵Ac]Ac-DOTA-SP in recurrent glioblastoma - tumour uptake.","authors":"Monika Tulik, Dariusz Pawlak, Radosław Kuliński, Frank Bruchertseifer, Przemysław Kunert, Leszek Królicki, Alfred Morgenstern, Jolanta Kunikowska","doi":"10.1007/s00259-025-07527-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07527-1","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144946543","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal changes in [¹⁸F]FDG PET brain metabolism as a prognostic marker in autoimmune encephalitis.","authors":"Denise Cerne, Stefano Raffa, Giulia Benvenuto, Giacomo Rebella, Pietro Mattioli, Giacomo Bavestrello, Anastasia Lechiara, Emanuela Maria Mobilia, Dario Arnaldi, Flavio Villani, Luca Roccatagliata, Giampaola Pesce, Matteo Pardini, Silvia Morbelli, Antonio Uccelli, Luana Benedetti, Federico Massa","doi":"10.1007/s00259-025-07526-2","DOIUrl":"https://doi.org/10.1007/s00259-025-07526-2","url":null,"abstract":"<p><strong>Purpose: </strong>Recent advancements in autoimmune encephalitis (AE) have enhanced diagnosis and management, but predicting long-term outcomes remains challenging. This study aims to evaluate longitudinal changes in brain [¹⁸F]FDG PET patterns in AE patients to identify specific regional metabolic variations and predict clinical outcomes.</p><p><strong>Methods: </strong>This longitudinal study compared brain [¹⁸F]FDG PET scans of 22 AE patients at baseline (BS) and after treatment follow-up (FU) using voxel-wise paired t-tests. Significant clusters with at least 100 voxels and p < 0.05 were identified and designated as volumes of interest (VOIs). The VOI values were correlated with main clinical outcomes using partial Spearman's tests, and their prognostic significance was assessed through regression models.</p><p><strong>Results: </strong>Three VOIs showed significant metabolic changes between baseline (BS) and follow-up (FU) assessments. VOI-A, which was relatively hypermetabolic at BS, included the caudate-thalamus-parahippocampal region, right amygdala, and anterior cingulate cortex. VOI-B1 and VOI-B2, relatively hypometabolic at BS, corresponded to the right fusiform gyrus, precuneus, and temporo-parietal cortex, respectively. Poorer metabolic recovery in all VOIs to normalcy correlated with greater disability (mRS) in both acute and post-therapy phases. Lower metabolism in BS VOI-B1 predicted higher Clinical Assessment Scale in Autoimmune Encephalitis (CASE) score at FU and relapses, while lower age was a significant predictor of escalation to second-line treatment.</p><p><strong>Conclusions: </strong>Longitudinal [¹⁸F]FDG PET reveals distinct regional metabolic changes paralleling clinical recovery post-treatment in AE. Temporo-parietal metabolism correlates with relapses, clinical severity, and functional impairment, highlighting [¹⁸F]FDG PET as a biological tracker of disease activity throughout AE and its prognostic value.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radioligand treatment with [¹⁷⁷Lu]Lu-PSMA I&T in elderly Patients - Safety, efficacy, and prognostic factors for survival.","authors":"Marcel Schwinger, Charis Kalogirou, Vincent Scheper, Maximiliane Däuwel, Simon Weber, Anna Katharina Seitz, Hubert Kübler, Andreas K Buck, Rudolf A Werner, Philipp E Hartrampf","doi":"10.1007/s00259-025-07519-1","DOIUrl":"https://doi.org/10.1007/s00259-025-07519-1","url":null,"abstract":"<p><strong>Purpose: </strong>We aimed to evaluate the safety and efficacy to explore predictors of prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) with [¹⁷⁷Lu]Lu-PSMA I&T in metastatic castration-resistant prostate cancer (mCRPC) patients aged ≥ 75 and explored baseline predictors of overall survival (OS).</p><p><strong>Materials and methods: </strong>56 men (median age 78, range 75-95) were treated with RLT. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Baseline Gleason score, blood parameters (PSA, LDH), and sites of metastases (bone, lymph nodes, liver, lung) were recorded. Quantitative PET parameters such as SUVmean (mean standardized uptake value), SUVpeak (peak standardized uptake value), SUVmax (maximum standardized uptake value), PSMA-TV (PSMApositive tumor volume), TL-PSMA (total lesion PSMA) were measured. PET response was assessed by RECIP 1.0 (response evaluation criteria in PSMA imaging); biochemical response by PCWG3 (prostate cancer working group 3). Associations with OS were analyzed via uni- and multivariable Cox regression and Kaplan-Meier curves.</p><p><strong>Results: </strong>No CTCAE grade III-V toxicities occurred. Grade I/II hematologic events included anemia (23.2%), leukocytopenia (18.6%) and thrombocytopenia (9.3%); eGFR declined by 2.5% (grade I/II in 18.6%). Median OS was 11 months; 60.7% of patients died. 74.4% of patients (32/43) showed PSA declines (median - 58%; 14/43 ≥ 50%). Higher baseline PSA (HR 1.001 per ng/mL; P < 0.10) and LDH (HR 1.008 per U/L; P < 0.01) were associated with shorter OS. Patients with progressive disease by both RECIP and PCWG3 had shorter OS than others (11 vs. 22 months; HR 3.3; P < 0.01). Any PSA response predicted longer OS (21 vs. 7 months; HR 0.3; P < 0.01). Presence of liver metastases portended poorer survival (8 vs. 21 months; HR 6.7; P < 0.001).</p><p><strong>Conclusion: </strong>[¹⁷⁷Lu]Lu-PSMA I&T RLT is well tolerated in patients ≥ 75 years. Lower baseline PSA and LDH but not PSMA-TV predict longer OS. Early PSA response strongly correlates with improved survival. Combined use of RECIP and PCWG3 criteria optimizes response assessment.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Preclinical and pilot clinical evaluation of novel dual-modality pet/fluorescence probes targeting FAP for accurate tumor margin delineation.","authors":"Liang Zhao, Yizhen Pang, Daqiang Xu, Jianhao Chen, Shan Yu, Dan Ruan, Lingyu Yu, Zhenyu Wu, Guoqiang Su, Hua Wu, Lin Ai, Long Sun, Di Fan, Haojun Chen","doi":"10.1007/s00259-025-07512-8","DOIUrl":"https://doi.org/10.1007/s00259-025-07512-8","url":null,"abstract":"<p><strong>Purpose: </strong>Accurate delineation of tumor margins and maximal safe resection are critical for successful curative oncologic surgery. However, fibroblast activation protein (FAP)-targeted probes suitable for fluorescence imaging remain limited. Here, we developed novel FAP-targeted fluorescent probes to accurately delineate tumor margins and enable rapid intraoperative identification of tumor boundaries in resected specimens.</p><p><strong>Methods: </strong>DOTA chelator for radiolabelling with gallium-68 was incorporated into dual-modality FAP-targeted probes synthesised by conjugating FAP-2286 and 3BP-3940 with the near-infrared (NIR) fluorophore IRDye800CW. These probes were evaluated both in vitro and in vivo using HEK293T-FAP cells stably expressing FAP and xenograft mouse models. Positron emission tomography (PET) and (NIR-II) fluorescence imaging assessed the specificity and ability of probes to delineate tumor margins. For clinical validation, resected lung tissue was incubated ex vivo with the probes. Tumor regions and margins were identified using fluorescence imaging and subsequently validated by haematoxylin and eosin (H&E) staining and FAP immunohistochemistry.</p><p><strong>Results: </strong>Both IRDye800CW-FAP-2286 and IRDye800CW-3BP-3940 exhibited high affinity for FAP-positive cells in vitro. PET imaging revealed high tumor specificity for both probes in vivo. In vivo and ex vivo NIR-II fluorescence imaging enabled accurate visualisation of tumor margins, with IRDye800CW-3BP-3940 exhibiting superior performance compared with IRDye800CW-FAP-2286. In the clinical specimen, IRDye800CW-3BP-3940 successfully delineated tumor regions with strong concordance to histopathological findings.</p><p><strong>Conclusion: </strong>We developed and validated a novel dual-modality molecular probe, IRDye800CW-3BP-3940, which integrated PET and NIR fluorescence imaging capabilities. This probe enabled highly specific detection of FAP-positive tumors and precise delineation of tumor margins in resected specimens.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144947360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Digital versus analogue PET in parathyroid imaging: comparison of PET metrics and machine learning-based characterisation of hyperfunctioning lesions (the DIGI-PET study).","authors":"Luca Filippi,Francesco Bianconi,Cristina Ferrari,Flavia Linguanti,Claudia Battisti,Nicoletta Urbano,Matteo Minestrini,Salvatore Gerardo Messina,Lisa Buci,Alfonso Baldoncini,Giuseppe Rubini,Orazio Schillaci,Barbara Palumbo","doi":"10.1007/s00259-025-07508-4","DOIUrl":"https://doi.org/10.1007/s00259-025-07508-4","url":null,"abstract":"PURPOSETo compare PET-derived metrics between digital and analogue PET/CT in hyperparathyroidism, and to assess whether machine learning (ML) applied to quantitative PET parameters can distinguish parathyroid adenoma (PA) from hyperplasia (PH).METHODSFrom an initial multi-centre cohort of 179 patients, 86 were included, comprising 89 PET-positive lesions confirmed histologically (74 PA, 15 PH). Quantitative PET parameters-maximum standardised uptake value (SUVmax), metabolic tumour volume (MTV), target-to-background ratio (TBR), and maximum diameter-along with serum PTH and calcium levels, were compared between digital and analogue PET scanners using the Mann-Whitney U test. Receiver operating characteristic (ROC) analysis identified optimal threshold values. ML models (LASSO, decision tree, Gaussian naïve Bayes) were trained on harmonised quantitative features to distinguish PA from PH.RESULTSDigital PET detected significantly smaller lesions than analogue PET, in both metabolic volume (1.32 ± 1.39 vs. 2.36 ± 2.01 cc; p < 0.001) and maximum diameter (8.35 ± 4.32 vs. 11.87 ± 5.29 mm; p < 0.001). PA lesions showed significantly higher SUVmax and TBR compared to PH (SUVmax: 8.58 ± 3.70 vs. 5.27 ± 2.34; TBR: 14.67 ± 6.99 vs. 8.82 ± 5.90; both p < 0.001). The optimal thresholds for identifying PA were SUVmax > 5.89 and TBR > 11.5. The best ML model (LASSO) achieved an AUC of 0.811, with 79.7% accuracy and balanced sensitivity and specificity.CONCLUSIONSDigital PET outperforms analogue system in detecting small parathyroid lesions. Additionally, ML analysis of PET-derived metrics and PTH may support non-invasive distinction between adenoma and hyperplasia.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"31 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Spatial imaging features derived from SUVmax location in resectable NSCLC are associated with tumor aggressiveness.","authors":"Zewen Jiang,Clemens Spielvogel,David Haberl,Josef Yu,Maximilian Krisch,Szabolcs Szakall,Peter Molnar,Janos Fillinger,Lilla Horvath,Ferenc Renyi-Vamos,Clemens Aigner,Balazs Dome,Christian Lang,Zsolt Megyesfalvi,Lukas Kenner,Marcus Hacker","doi":"10.1007/s00259-025-07528-0","DOIUrl":"https://doi.org/10.1007/s00259-025-07528-0","url":null,"abstract":"PURPOSEAccurate non-invasive prediction of histopathologic invasiveness and recurrence risk remains a clinical challenge in resectable non-small cell lung cancer (NSCLC). We developed and validated the Edge Proximity Score (EPS), a novel [18F]FDG PET/CT-based spatial imaging feature that quantifies the displacement of SUVmax relative to the tumor centroid and perimeter, to assess tumor aggressiveness and predict progression-free survival (PFS).METHODSThis retrospective study included 244 NSCLC patients with preoperative [18F]FDG PET/CT. EPS was computed from normalized SUVmax-to-centroid and SUVmax-to-perimeter distances. A total of 115 PET radiomics features were extracted and standardized. Eight machine learning models (80:20 split) were trained to predict lymphovascular invasion (LVI), visceral pleural invasion (VPI), and spread through air spaces (STAS), with feature importance assessed using SHAP. Prognostic analysis was conducted using multivariable Cox regression. A survival prediction model incorporating EPS was externally validated in the TCIA cohort. RNA sequencing data from 76 TCIA patients were used for transcriptomic and immune profiling.RESULTSEPS was significantly elevated in tumors with LVI, VPI, and STAS (P < 0.001), consistently ranked among the top SHAP features, and was an independent predictor of PFS (HR = 2.667, P = 0.015). The EPS-based nomogram achieved AUCs of 0.67, 0.70, and 0.68 for predicting 1-, 3-, and 5-year PFS in the TCIA validation cohort. High EPS was associated with proliferative and metabolic gene signatures, whereas low EPS was linked to immune activation and neutrophil infiltration.CONCLUSIONEPS is a biologically relevant, non-invasive imaging biomarker that may improve risk stratification in NSCLC.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"84 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Insulinoma diagnosis and characterization with intratumoral heterogeneity employing [18F]FB(ePEG12)12-exendin-4 PET/MRI.","authors":"Hayao Yoshida,Takaaki Murakami,Kanae Kawai Miyake,Yoichi Shimizu,Koji Itagaki,Kentaro Sakaki,Daisuke Otani,Hiroyuki Fujimoto,Daisuke Yabe,Nobuya Inagaki,Yuji Nakamoto","doi":"10.1007/s00259-025-07513-7","DOIUrl":"https://doi.org/10.1007/s00259-025-07513-7","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"44 1","pages":""},"PeriodicalIF":9.1,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[18F]F-FAPI PET/CT outperforms [18F]F-FDG PET/CT in predicting treatment response in lupus nephritis.","authors":"Min Zhao, Chunqing Zhou, Hao Fang, Yan Cao, Marcus Hacker, Xiang Li, Muyao Guo, Xiaoping Yi, Xiaoli Zhang","doi":"10.1007/s00259-025-07523-5","DOIUrl":"10.1007/s00259-025-07523-5","url":null,"abstract":"<p><strong>Purpose: </strong>To identify predictors of complete response (CR) following induction therapy in lupus nephritis (LN) and comparatively evaluate the predictive value of baseline [18 F]F-FAPI PET/CT versus [18 F]F-FDG PET/CT for treatment short-term outcomes.</p><p><strong>Materials and methods: </strong>Twenty biopsy-proven LN patients were prospectively enrolled and underwent dual-tracer PET/CT imaging, using both [18 F]F-FAPI and [18 F]F-FDG imaging prior to standardized induction therapy. Treatment response was assessed at 6 months, categorizing into CR, partial response (PR), and non-response (NR) groups. Associations between PET metrics, clinical biomarkers and treatment response were analyzed. Semiquantitative PET parameters including renal standardized uptake values (SUVmax) and target-to-background ratio (TBR) were calculated.</p><p><strong>Results: </strong>Baseline renal FAPI SUVmax was inversely correlated with estimated glomerular filtration rate (eGFR) and positively with erythrocyte sedimentation rate (ESR) (P < 0.05 for both), whereas FDG SUVmax showed no significant correlation with either parameter. At 6 months, 50% of patients achieved CR, 25% PR, and 25% NR. Patients with CR exhibited significantly lower baseline renal FAPI SUVmax and TBR compared to those with non-CR (PR + NR) (P < 0.01). Visual assessment of FAPI uptake outperformed FDG in predicting CR, with higher accuracy (85% vs. 70%), specificity (90% vs. 50%), and positive predictive value (PPV, 89% vs. 64%), while sensitivity and negative predictive value (NPV) were comparable. Univariate logistic regression identified age > 35 years (P < 0.05) and negative baseline FAPI uptake (P < 0.01) as significant predictors of CR. In multivariate analysis, negative FAPI uptake remained the only independent predictor (P < 0.01).</p><p><strong>Conclusion: </strong>[18 F]F-FAPI PET/CT demonstrates superior predictive performance over [18 F]F-FDG PET/CT for short-term treatment response in lupus nephritis. It holds promise as a noninvasive imaging biomarker to guide clinical decision-making and optimize individualized therapy.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mini-review and situation report on the role and usefulness of nuclear medicine imaging for malaria.","authors":"Janie Duvenhage, Jan Rijn Zeevaart, Mike Machaba Sathekge, Thomas Ebenhan","doi":"10.1007/s00259-025-07443-4","DOIUrl":"10.1007/s00259-025-07443-4","url":null,"abstract":"<p><p>Malaria remains one of the deadliest parasitic diseases globally. Delay or failure in treatment can lead to the development of severe malaria. Severe malaria, an understudied multisystem disease, affects the host's organs and can lead to several syndromes and serious complications, some effecting life-long neurological and cognitive sequela. There is a lack in knowledge regarding the molecular mechanisms underlying severe malaria pathogenesis, and research has mostly relied on post-mortem studies and animal models, both of which lack translatability to human malaria. This review presents the clinical nuclear imaging techniques used in malaria. Although the presented radiopharmaceuticals have added value to understand some aspects of severe malaria, there has been in stagnation in development of more malaria-specific radiopharmaceuticals. This manuscript highlights the current limitations for implementing improved radiopharmaceuticals and provides valuable insights on how these challenges can be overcome.</p>","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Associated Myositis: Paraneoplastic syndrome.","authors":"Filip Gemmel, Thomas Helleputte, Anouck Ottevaere, Kathia De Man","doi":"10.1007/s00259-025-07502-w","DOIUrl":"https://doi.org/10.1007/s00259-025-07502-w","url":null,"abstract":"","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":" ","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}